Lv1
40 积分 2025-11-02 加入
Evolving roles of MET as a therapeutic target in NSCLC and beyond
5个月前
已完结
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
5个月前
已完结
皖公网安备34019202002308
